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Abstract
Background: This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt
pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine
uptake in non-thyroid cancer cells.
Methods: We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on
NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon
carcinoma, breast carcinoma, and brain cancers. We also examined radioiodine uptake and histone acetylation at the NIS
promoter in selected cells.
Results: Overall, the three inhibitors could induce NIS expression, to various extents, in melanoma and all the epithelial
carcinoma-derived cells but not in brain cancer-derived cells. SAHA was most effective and its effect could be significantly
enhanced by RDEA119 and perifosine. The expression of NIS, at both mRNA and protein levels, was most robust in the
melanoma cell M14, hepatic carcinoma cell HepG2, and the gastric carcinoma cell MKN-7 cell. Radioiodine uptake was
correspondingly induced, accompanied by robust increase in histone acetylation at the NIS promoter, in these cells when
treated with the three inhibitors.
Conclusions: This is the first demonstration that simultaneously suppressing the MAP kinase and PI3K/Akt pathways and
HDAC could induce robust NIS expression and radioiodine uptake in certain non-thyroid human cancer cells, providing
novel therapeutic implications for adjunct radioiodine treatment of these cancers.
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Introduction
As a transmembrane glycoprotein expressed primarily in
follicular epithelial thyroid cells, sodium iodide symporter (NIS)
plays a fundamental role in the transportation of iodide from the
extracellular space into the thyroid cell for synthesis of thyroid
hormones in the thyroid gland [1–4]. This is the biological basis
for the clinical application of radioiodine in the diagnosis and
treatment of a variety of benign and malignant thyroid diseases. A
typical example of utilizing this function of NIS is the radioiodine
ablation widely applied for the treatment of thyroid cancer [5,6].
Radioiodine treatment is usually effective in thyroid cancer
patients, but it becomes ineffective when thyroid cancer cells have
lost the expression of NIS and can no longer take up radioiodine as
typically seen in poorly differentiated and undifferentiated thyroid
cancers [7–10]. Previous studies demonstrated that inhibitors of
histone deacetylase (HDAC) could induce the expression of NIS in
thyroid cancer cells [11,12]. We recently demonstrated that
combination of the HDAC inhibitor SAHA with inhibitors of the
MAP kinase and PI3K/Akt pathways could induce robust and
synergistic expression of NIS and radioiodine uptake in thyroid
cancer cells [13]. This opened the possibility for novel effective
treatment of thyroid cancer using radioiodine that is otherwise
non-avid for this radioisotope.
Given the unique function of NIS to transport iodide into
thyroid cells and the clinical success of using radioiodine for
thyroid cancer ablation treatment, it has long been proposed and
tested that exogenously induced NIS expression using targeted
gene transfer can confer non-thyroid cancer cells radioiodine
avidity for radioiodine ablation treatment [2–4,14]. Such studies
are promising but have not yet resulted in reliable clinical
applications. Major effort is still needed to improve several key
aspects of this approach, including the therapeutic efficacy,
specificity, safety, and technical complexity. NIS can be expressed
in various normal non-thyroid tissues, although at a low level,
including, for example, salivary, lacrimal, breast, stomach,
intestine, lung, and kidney tissues [15–19]. Low-level expression
of NIS was also reported in some non-thyroid cancers such as
breast carcinoma [20]. We recently demonstrated that suppression
of the MAP kinase and PI3K/Akt pathways could induce
expression of NIS and radioiodine uptake in melanoma cells
[21]. Given the synergism in robustly inducing thyroid gene
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simultaneously inhibiting HDAC and the MAP kinase and PI3K/
Akt pathways [13], in the present study we tested the potential of
this novel therapeutic strategy to induce NIS expression for
radioiodine uptake in an extended panel of non-thyroid cancer
cells.
Results
Induction of NIS gene expression in non-thyroid cancer
cells by suppressing the MAP kinase and PI3K/AKT
pathways and HDAC
We tested the effects of the MEK inhibitor RDEA119, the Akt
inhibitor perifosine, and the HDAC inhibitor SAHA on the
expression of the NIS gene in 13 human cancer cells (Table 1).
These included melanoma cells and epithelial carcinoma cells
derived from hepatocarcinoma, gastric carcinoma, colon carcino-
ma, and breast cancer, as well as glioblastoma cell T98G and
astrocytoma cell SNB-78. To demonstrate the targeted drug effects
of the three inhibitors in these cells, we first tested their effects on
their target molecules in the signaling pathways. As shown in
Fig. 1, after 30 hrs of treatment, RDEA119 at 0.5 mM and
perifosine at 5 mM could significantly inhibit the phosphorylation
of ERK (p-ERK) and the phosphorylation of AKT (p-AKT),
respectively, in virtually all the cells except for the SNB-78 cell.
SAHA at 0.5 mM for 30 hrs could dramatically enhance the
acetylation of histone H3 in these cells except for few cells, such as
T98G and SNB78, in which there was no or only a small increase
in histone acetylation. These results, overall, demonstrated the
expected target effects of these inhibitors.
We subsequently tested the effects of the three inhibitors at these
concentrations, individually or in combinations, on the expression
of the NIS gene in the 13 cells using quantitative real-time PCR. As
shown in Table 1, NIS expression was increased to various extents
in all the cells, except for the two non-epithelial cancer cells T98G
and SNB78 which did not have any response to these drug
treatments. The induced NIS expression was most robust in the
melanoma cell M14, the hepatocarcinoma cell HepG2, and the
gastric carcinoma cell MKN-7, which were used for further studies
as presented in the following sections. Individually, RDEA119 and
perifosine each had a smaller effect and SAHA displayed the most
pronounced effects on the expression of NIS. A synergistic effect
was seen when the MEK inhibitor or the Akt inhibitor was each
combined with SAHA and the synergistic effects were even more
robust when the three drugs were combined, with an exception
that in HepG2 cells perifosine did not enhance further the robust
effect of SAHA.
Following the demonstration of mRNA expression of NIS by
quantitative real-time PCR in melanoma and epithelial carcinoma
cells, we next sought to examine the expression of NIS at the
protein level in these cells, using the melanoma cell M14,
hepatocarcinoma cell HepG2, and gastric carcinoma cell MKN-
7 as representatives which displayed the most robust expression of
NIS (Table 1). As shown in Fig. 2, combination treatment of these
cells with RDEA119, perifosine and SAHA significantly increased
NIS protein expression as detected by Western blotting.
Compared with M14 and HepG2 cells, MKN-7 cells displayed a
modest increase in the expression of NIS protein in response to the
combination treatment with the three inhibitors, which was similar
to the pattern of NIS mRNA expression in these cells under this
drug treatment condition (Table 1). Thus, suppressing the MAP
kinase and PI3K/Akt pathways and HDAC could induce robust
expression of NIS in these cells both at the transcriptional and
translational levels.
Cellular radioiodide uptake induced by suppressing the
MAP kinase and PI3K/Akt pathways and HDAC
With the demonstration of robust NIS expression in non-
thyroid cancer cells by suppressing the MAP kinase and PI3K/Akt
pathways and HDAC, we used M14, HepG2 and MKN-7 cells to
test the ultimate functional relevance of this finding by examining
the ability of these cells to take up radioiodide after induction of
NIS. As shown in Fig. 3, radioiodide uptake was clearly induced in
these cells by the combination treatment with RDEA119,
perifosine and SAHA. Among the three cells, marked radioiodide
uptake was particularly seen in the M14 cell, consistent with the
finding that NIS expression at both mRNA and protein levels was
most robust in this cell.
Table 1. NIS mRNA expression in different human cancer cells after drug treatments (mean6SD).*
RD PE SA RD+PE RD+SA PE+SA RD+PE+SA
Melanoma M14 13.3±2.9 2.7±0.5 145.6±1.1 11.2±2.5 554.2±15.5 225.6±16.7 661.3±19.3
A375 5.361.4 1.060.1 6.163.8 4.161.3 8.961.9 4.663.1 6.261.5
UACC-62 0.760.1 2.060.8 4.860.8 0.560.2 3.961.3 18.364.9 6.664.8
Liver HepG2 3.1±0.9 1.2±0.2 64.1±15.8 3.2±0.5 77.5±1.9 64.7±9.3 74.4±29.4
SK-Hep-1 1.960.5 1.760.4 6.962.1 1.760.4 8.162.5 8.060.6 9.862.8
Gastric MKN-7 6.0±0.1 1.5±0.3 11.5±0.1 4.5±1.3 19.4±3.2 18.5±5.2 25.1±4.2
NUGC-4 1.160.5 1.661.3 6.762.1 0.860.5 8.260.1 6.260.4 5.560.6
Breast MDA-MB-231 2.461.0 0.460.1 1.360.1 2.460.6 5.362.6 2.060.3 3.660.9
BT-20 2.361.3 1.261.0 7.265.0 2.661.9 4.262.7 4.862.2 5.262.7
Colon RKO 2.160.1 1.560.6 2.360.9 3.362.0 3.161.2 2.260.8 4.061.1
HT-29 3.161.0 0.660.3 1.360.9 3.861.6 5.560.9 0.960.7 6.062.3
Non-epithelial T98G 1.360.7 0.760.2 1.860.4 0.660.3 1.760.6 1.760.5 1.460.1
SNB78 0.860.2 0.660.1 0.760.1 1.160.4 0.960.2 1.160.1 1.160.3
*The data in the table represent folds of increase in NIS expression over the control treatment with DMSO/PBS as described in the Materials and Methods. RD, RDEA119;
PE, perifosine; SA, SAHA.
doi:10.1371/journal.pone.0031729.t001
NIS Expression in Non-Thyroid Cancers
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31729Enhancement of histone acetylation of the NIS promoter
by suppressing the MAP kinase and PI3K/Akt pathways
and HDAC
Histone acetylation at the promoter region promotes gene
expression [22]. To explore whether this was a mechanism
involved in the expression of NIS induced by the drug treatments
in non-thyroid cancer cells in the present study, we next performed
ChIP analysis of histone acetylation at the NIS promoter. We
examined three different regions of the NIS promoter for histone
H3 and H4 acetylation in M14, HepG2 and MKN-7 cells. These
regions represent the minimal essential NIS promoter [23]. We
found that histone acetylation at these regions of the NIS promoter
was increased to various levels by treatment with SAHA in these
cells (Fig. 4a–c). Combination treatment with the MAP kinase and
PI3K/Akt pathways and HDAC inhibitors increased further
histone acetylation at the NIS promoter. Overall, this histone
acetylation was seen in both H3 and H4 in the three cells except
for MKN-7 cells in which no significant acetylation change was
seen in H3 (Fig. 4c). All the three regions of the minimal essential
NIS promoter displayed histone acetylation except for the P1
region in M14 cells that showed no change in acetylation of H3
after drug treatments (Fig. 4a). Up to about 50 folds of increase in
histone H4 acetylation at the P2 region of the NIS promoter in
M14 cells (Fig. 4a) and about 20 folds of increase in histone H4
acetylation at the P1 region in HepG2 cells (Fig. 4b) were
observed. These data suggest that histone acetylation is a
mechanism involved in the NIS expression induced by suppressing
the MAP kinase and PI3K/Akt pathways and HDAC in these
non-thyroid cancer cells. M14 cells showed the most robust
histone acetylation at the NIS promoter and second most in
HepG2 cells. MKN-7 cells displayed a relatively modest histone
acetylation at the NIS promoter. It is interesting to note that this
pattern of the extent of histone acetylation in the three cells echoed
well the patterns of the extent of NIS expression (Table 1, Fig. 2)
and radioiodine uptake (Fig. 3) in these cells, further supporting an
important role of histone acetylation in the NIS expression
induced by targeting the MAP kinase and PI3K/Akt pathways
and HDAC. This does not seem to apply to the T98G cell which
showed some histone acetylation under the treatment with SAHA
(Fig. 1) while there was no increase in NIS expression in this cell
(Table 1). However, this acetylation level of histone was minimal
in comparison with that in many other cells (Fig. 1). Therefore, the
correlation of NIS expression with histone acetylation was overall
clear in various cells tested.
Figure 1. Target effects of inhibitors of the MAP kinase and PI3K/Akt pathways and HDAC in various non-thyroid human cancer
cells. The MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA were used to respectively target these signaling
pathways or molecules. Cells were treated for 30 hrs with 0.5 mM RDEA119, 5 mM perifosine or 0.5 mM SAHA as indicated. DMSO or PBS was used in
parallel as the vehicle control. Cells were lysed for Western blotting after treatments to reveal the levels of phosphorylated ERK (p-ERK),
phosphorylated Akt (p-Akt), and acetylated histone (Ac-His) with specific antibodies. ‘‘+’’, treatment with the indicated inhibitor; ‘‘2’’, treatment with
vehicle.
doi:10.1371/journal.pone.0031729.g001
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Radioiodine ablation and adjuvant therapy are classical and
standard treatments for thyroid cancer, which takes advantage of
the unique iodide-transporting function of NIS in the thyroid cell
membrane. Given the fact that NIS is also normally expressed, to
various extents, in several non-thyroid tissues, in the present study
we tested NIS expression and radioiodine uptake in cancer cells
derived from non-thyroid tissues by simultaneously suppressing the
MAP kinase and PI3K/Akt pathways and HDAC. Although the
role of MAP kinase and PI3K/Akt pathways in the expression of
NIS was investigated in melanoma in our previous studies [21], the
role of HDAC and histone acetylation in the expression of NIS in
melanoma has not been investigated. We therefore also included
melanoma cells in the present study.
We were able to induce expression of NIS, to various extents, in
melanoma cells and hepatic, gastric, colon and breast carcinoma
cells, but not in non-epithelial brain tumor-derived cells,
suggesting that this inducible NIS expression may be restricted
to skin cancer cells and cancer cells of epithelial cell origin. This is
interestingly consistent with the distribution pattern of physiolog-
ical uptake of radioiodine in the tissues of skin (recovery phase of
burn), liver, stomach, colon, and breast (lactating phase) on the
body scan of thyroid cancer patients after radioiodine treatment
[24–27]. Remarkably, we also demonstrated radioiodine uptake
following the induced expression of NIS, consistent with NIS
functionality in these non-thyroid cancer cells. Our data also for
the first time showed that increased histone acetylation at the NIS
promoter was an important mechanism involved in the expression
of NIS in these non-thyroid cancer cells.
HDAC inhibitor-induced NIS expression was previously
demonstrated in Hela cells and, as in the same study, in HepG2
cells [28]. To take a further step, we recently demonstrated a
synergistic effect of the HDAC inhibitor SAHA on NIS expression
induced by suppressing the MAP kinase and PI3K/Akt pathways
in thyroid cancer cells although, in this study, histone acetylation
was not examined [13]. In the present study, we for the first time
directly demonstrated that suppression of the MAP kinase and
PI3K/Akt pathways enhanced histone acetylation at the NIS
promoter as a mechanism for the expression of NIS induced by
simultaneously targeting the two pathways and HDAC in human
cancer cells.
Demonstration of NIS expression at both mRNA and protein
levels as well as radioiodide uptake in these cells established the
functional significance of the inducible expression of the NIS gene
in these non-thyroid cancer cells. The level of induced NIS
Figure 2. Western blotting analysis of NIS protein expression in
M14, HepG2 and MKN-7 cells after treatment with the MEK,
Akt and HDAC inhibitors. Cells were treated for 30 hrs with
combination use of RDEA119, perifosine, and SAHA at the concentra-
tions described in Fig. 1, followed by standard Western blotting analysis
of cell lysates using the specific primary antibody against NIS. The
expression level of ß-actin was analyzed in parallel for quality control.
‘‘Control’’, treatment of cells with vehicle; ‘‘R+P+S’’, treatment of cells
with combined use of RDEA119, perifosine and SAHA.
doi:10.1371/journal.pone.0031729.g002
Figure 3. Induction of radioiodine uptake in M14, HepG2 and MKN-7 cells by treatment with the MEK, Akt and HDAC inhibitors.
Cells were treated with RDEA119, perifosine and SAHA as described in Fig. 2, followed by incubation with Na
125I for 1 hr. Parallel cells were
additionally treated with the NIS blocker NaClO4 to obtain non-specific radioiodine uptake/binding with the cells. Cells were then washed, lysed, and
measured for radioactivity. Cell radioiodine uptake is presented as cpm/10
6 cells (on the y-axis of the figure) after correction for the non-specific
radioiodine binding. Detailed experimental procedures are as described in the Materials and Methods. ‘‘Control’’, treatment of cells with vehicle;
‘‘R+P+S’’, treatment of cells with combination use of RDEA119, perifosine and SAHA. ** In comparison with control, p,0.01.
doi:10.1371/journal.pone.0031729.g003
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hepatic carcinoma cell HepG2, and gastric carcinoma cell MKN-7
showing the most robust expression of NIS, suggesting that NIS
expression and radioiodine uptake can be induced preferentially in
certain specific cases of these cancers for unclear reasons.
Additional factors likely exist that determine the inducibility of
NIS expression in these cancer cells, as exemplified by the estrogen
receptor status that determines the inducibility of NIS expression
by all-trans retinoic acid in breast cancer cells [29]. The results of
the present study have important clinical implications. Melanoma,
hepatic carcinoma, and gastric carcinoma are common human
cancers, all with high mortality rates, particularly in metastatic and
advanced cases. As the latter cases are usually surgically
inoperable, novel effective medical treatments are currently
urgently needed. With the inducibility of NIS expression and
radioiodine uptake in these cancer cells demonstrated in the
present study, it may be possible to treat these cancers using
adjunct radioiodine as in the treatment for thyroid cancer. The
fact that induced NIS expression was particularly robust in some
cell lines but not others derived from these cancers suggests that
this radioiodine treatment may be effective in a subgroup of
patients with these cancers.
Therapeutic agents targeting major signaling pathways, such as
MEK and BRAF inhibitors for the MAP kinase pathway and Akt
and mTOR inhibitors for the PI3K/Akt pathway, as well as
HDAC inhibitors, are currently being actively developed clinically
[30–33]. Many of them have shown strong therapeutic potential in
various human cancers and some have been approved for clinical
use. It is therefore clinically possible to use these inhibitors to
target the MAP kinase and PI3K/Akt pathways and some of them
in combination to dually suppress the two pathways to induce NIS
expression. The HDAC inhibitor SAHA, which has also been
approved for the treatment of certain cancers [34], can be
included in this drug combination therapy to enhance NIS
expression for radioiodine treatment of cancers. As these drugs are
themselves therapeutic by directly inhibiting cancer cell growth,
their use in conjunction with radioiodine use to further kill cancer
cells could make the treatment an even more effective chemo-
therapy. This may prove to be a novel and particularly effective
therapeutic strategy for melanoma and carcinomas of the hepatic
and gastrointestinal system. This technically easy strategy of using
clinically proven drugs to induce NIS expression and radioiodine
uptake in non-thyroid cancer cells, if confirmed to be effective in
future studies, might prove to be superior to NIS expression
achieved by gene transfer approaches as it can avoid certain safety,
specificity, efficacy, and technical complexity issues associated with
the widely investigated plasmid- or virus-mediated organ-targeted
NIS gene transfer [4,14].
Interestingly, previous studies demonstrated a basal expression
of thyroid genes in skin cells and melanoma cells [35,36]. This
provides a basis for the robustly induced expression of thyroid
genes and radioiodine uptake in melanoma cells by targeting the
MAP kinase and PI3K/Akt pathways and HDAC in our present
and previous studies [21]. It is also possible but remains to be
investigated that a low basal expression state of thyroid genes
similarly exists in hepatic and gastric carcinomas and other
cancers examined in the present study that becomes robustly
active upon suppression of the major signaling pathways.
In summary, the present study for the first time demonstrates
robust NIS expression and radioiodine uptake in several non-
thyroid cancer cells by simultaneously targeting the MAP kinase
and PI3K/Akt pathways and HDAC using their inhibitors. As
many of these inhibitors have already been proven to be clinically
feasible and promising in inhibiting various cancers, their use to
also induce NIS expression for adjuvant radioiodine treatment in
addition to their direct inhibition of cancer cells may prove to be a
novel and effective therapeutic strategy for selected non-thyroid
cancers.
Materials and Methods
Human cancer cell lines
Thirteen human cancer cell lines were used in this study,
including melanoma cells M14, UACC-62 and A375; hepatic
carcinoma cells HepG2 and SK-Hep-1; gastric carcinoma cells
MKN-7 and NUGC-4; colon carcinoma cells HT-29 and RKO;
breast carcinoma cells BT-20 and MDA-MB-231; glioblastoma
cell T98G; and astrocytoma cell SNB-78. These cells were from
American Type Culture Collection (Manassas, VA) and NCI-
Frederick Cancer DCTD Tumor/Cell Line Repository (Frederick,
MD). M14, UACC-62, MKN-7, NUGC-4 and SNB-78 cells were
cultured in RPMI 1640 medium (Mediatech, Inc., Manassas, VA)
with 10% fetal bovine serum (Invitrogen Corp. Carlsbad, CA).
RKO, BT-20, MDA-MB-231, HepG2, SK-Hep-1, and T98G
cells were cultured in Eagle’s Minimum Essential Medium
(ATCC, Manassas, VA) with 10% fetal bovine serum. The HT-
29 cells were cultured in McCoy’s 5a Medium (ATCC, Manassas,
VA) with 10% fetal bovine serum. The A375 cells were cultured in
Dulbecco’s Modified Eagle’s Medium (ATCC, Manassas, VA)
with 10% fetal bovine serum. All the cells were grown at 37uC
with 5% CO2.
Under these culture conditions, cells were treated, where
indicated, with the MEK inhibitor RDEA119, the Akt inhibitor
perifosine, and the HDAC inhibitor SAHA individually or in
combinations. DMSO and PBS were used in parallel as the vehicle
control.
Western blotting
Cells were lysed in RIPA buffer with standard protease
inhibitors (Santa Cruz Biotechnology, Santa Cruz, CA) and
Figure 4. Effects of the treatment with MEK, Akt and HDAC inhibitors on histone acetylation at the NIS promoter in M14, HepG2
and MKN-7 cells. Cells were treated with SAHA alone or SAHA in combination with RDEA119 and perifosine as described in Fig. 2. Histone
acetylation levels at the three regions (P1, P2, and P3) that comprise the minimal essential promoter of the NIS gene were analyzed by chromatin
immunoprecipitation (ChIP) analysis as described in Materials and Methods. Acetylation status of both histone H3 and H4 was examined using
specific antibodies for ChIP. Non-specific IgG antibodies were used as control. The results for M14, HepG2 and MKN-7 cells are presented in Figs. 4a,
4b and 4c, respectively. For each cell, the upper panel shows the actual results of PCR on the DNA fragments obtained by ChIP using non-specific
control IgG, anti-acetylated H3 (Anti Ac-H3) antibody or anti-acetylated H4 (Anti Ac-H4) antibody. Identical amounts of pre-immunoprecipitation cell
lysates from different treatment conditions were used to start the immunoprecipitation. An aliquot of pre-immunoprecipitation cell lysate was
directly used to isolate DNA as ‘‘Input’’ control. The PCR results reflect the histone acetylation levels. Presented in the lower panel for each cell is a bar
graph showing quantitatively the acetylation levels of H3 and H4 at the three regions of NIS promoter based on densitometric measurements of the
upper panel. The results are normalized by dividing the corresponding input signals and are presented as the ratio of the indicated treatment over
the control. ‘‘Control’’, treatment of cells with vehicle; ‘‘SAHA’’, treatment of cells with SAHA alone; ‘‘R+P+S’’, treatment of cells with combined use of
RDEA119, perifosine and SAHA.
doi:10.1371/journal.pone.0031729.g004
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previously [37] using primary antibodies, including anti-phospho-
ERK, anti-phospho-Akt, anti-Ac-Histone H3, or anti-actin (Santa
Cruz Biotechnology, Santa Cruz, CA); anti-Ac-Histone H4 (Cell
Signaling, Danvers, MA); or anti-NIS antibodies (Millipore Corp.,
Billerica, MA).
RNA extraction and quantitative real-time PCR
After a 30-h treatment of cells with the indicated inhibitors, total
RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad,
CA) following instructions of the manufacturer. Three mg total
RNA was reverse-transcribed using Oligo-dT primers and
superscript III RT (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Quantitative real-time PCR was
preformed to analyze the expression of the NIS gene using iTaq
SYBR Green Supermix with ROX (Bio-rad, Hercules, CA) on a
ABI 7900HT PCR system (Applied Biosystems, Foster City, CA).
b-actin was run in parallel to standardize the input cDNA. The
primers designed for NIS and b-actin genes and the methods used
to calculate relative expression levels of NIS were as described
previously [13].
Radioactive iodide uptake assay
The radioactive iodide uptake assay was performed as described
previously [13]. Briefly, after a 30-h treatment with the indicated
inhibitors, cells were incubated with 1 mCi Na
125I and 5 mM
nonradioactive NaI in 2 ml medium on 6-well plates at 37uC for
1 hr. To determine the NIS-specific uptake, parallel cells similarly
treated with the inhibitors were additionally treated with 200 mM
NaClO4 for 30 min prior to Na
125I treatment. The medium was
aspirated and cells were quickly washed three times with Hank’s
balanced salt solution (Sigma-Aldrich, St. Louis, MO). Cells were
then trypsinized and lysed with 1 ml 0.33 M NaOH. Parallel
plates of cells identically treated with the inhibitors but without
radioiodine incubation were used to determine the number of cells
at the end of the experiment. The radioactivity associated with
cells was counted with a gamma counter and presented as cpm/
10
6 cells after correction for non-specific radioiodide binding of
cells in the presence of NaClO4.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the EZ-Magna ChIP A kit
(Millipore Corp., Billerica, MA) according to the manufacturer’s
protocol. Briefly, after drug treatments, 1610
7 cells were cross-
linked with 37% formaldehyde for 10 min, followed by incubation
with the glycine solution provided in the kit for 5 min. After 2
washings with PBS, cells were lysed and sonicated 12 times for
10 seconds at 20% pulse power using the Sonifier Cell Disrupter
Model Micros-150D (Branson, Danbury, CT). The cross-linked
protein/DNA was subsequently incubated overnight with anti-
acetylated histone H3, anti-acetylated histone H4 antibodies or
control non-specific IgG, and purified using protein A beads. After
washing with the buffers in the kit in the order per the provided
protocol, protein A beads with protein/DNA complexes were
incubated with proteinase K at 62uC for 2 hours with shaking.
DNA fragments were separated subsequently by centrifugation
and purified using spin columns. Three pairs of primers spanning
the minimal essential promoter area of the NIS gene were used in
the analysis as described previously [23]. Standard end-point PCR
was performed as follows: after 3 min denaturing at 95uC, the
reaction mixture was run for 32 cycles at 94uC, 60uC, and 72Cu
each for 30 sec, followed by an elongation at 72uC for 8 min (for
all three pairs of primers).
Statistical Analysis
The data presented here are representatives of at least two
similar experiments performed in duplicates or triplicates. The
differences between groups were analyzed by t test and a P value
less than 0.05 was considered significant.
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